Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
暂无分享,去创建一个
S. Günther | H. Will | T. Santantonio | M. Sterneck | M. Jung | L. Fischer | G. Gaeta | F. von Breunig
[1] F. Zoulim,et al. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance , 1999, Hepatology.
[2] K. Walters,et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .
[3] Y. Cheng,et al. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.
[4] R. D. de Man,et al. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. , 1998, The Journal of infectious diseases.
[5] R. Liang,et al. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. , 1998, Journal of hepatology.
[6] J. Wands,et al. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.
[7] K. Korn,et al. Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. , 1997, Transplantation.
[8] R. D. de Man,et al. Lamivudine resistance inimmunocompetent chronic hepatitis B , 1997 .
[9] S. Locarnini,et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro , 1997, Hepatology.
[10] I. Marino,et al. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. , 1997, Transplantation.
[11] P. Angus,et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. , 1997, Journal of hepatology.
[12] G. Pape,et al. Role for CD4 positive T cell response in the pathogenesis of hepatitis B. , 1997, Journal of hepatology.
[13] R. Lanford,et al. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase , 1997, Journal of virology.
[14] F. Zoulim,et al. Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription , 1997 .
[15] K. Reddy,et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.
[16] A. Burroughs,et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis , 1996, The Lancet.
[17] T. Shaw,et al. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir , 1996, Hepatology.
[18] R. Tubiana,et al. Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.
[19] D. Tyrrell,et al. Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.
[20] E. Elias,et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine , 1996, Hepatology.
[21] T. Berg,et al. Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation , 1996, Transplant international : official journal of the European Society for Organ Transplantation.
[22] D. Tyrrell,et al. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro , 1996, Antimicrobial agents and chemotherapy.
[23] M. Manns,et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. , 1996, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[24] H. Thomas,et al. A double blind, placebo‐controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection , 1996, Journal of viral hepatitis.
[25] B. Korba,et al. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells , 1996, Antimicrobial agents and chemotherapy.
[26] E. Schiff,et al. A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.
[27] D. Tyrrell,et al. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine , 1995, Antimicrobial agents and chemotherapy.
[28] M. Manns,et al. Prostaglandin E plus famciclovir--a new concept for the treatment of severe hepatitis B after liver transplantation. , 1994, Transplantation.
[29] S. Locarnini,et al. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus , 1994, Antimicrobial Agents and Chemotherapy.
[30] F. Zoulim,et al. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase , 1994, Journal of virology.
[31] R. Hodge. Famciclovir and Penciclovir. The Mode of Action of Famciclovir Including Its Conversion to Penciclovir , 1993 .
[32] D. Earnshaw,et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus , 1992, Antimicrobial Agents and Chemotherapy.
[33] R. Schinazi,et al. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[34] G. Radziwill,et al. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity , 1990, Journal of virology.
[35] I Sauvaget,et al. Identification of four conserved motifs among the RNA‐dependent polymerase encoding elements. , 1989, The EMBO journal.